LAUSR

Aim Centrally‐acting acutely anxiolytic drugs, such as benzodiazepines, barbiturates and gabapentinoids, affect various central nervous system (CNS) functions, which reflects not only their anxiolytic effects but also neuropsychological side‐effects. To validate the pharmacodynamic biomarkers for GABA‐ergic anxiolytics, this study determined the pharmacodynamics of two anxiolytics and a nonanxiolytic control, and linked them to their anxiolytic and sedative effects, during an anxiety‐challenge study day. Methods Twenty healthy volunteers were randomized in this placebo‐controlled, double‐blind, four‐way cross‐over study with single‐dose alprazolam (1 mg), diphenhydramine (50 mg), pregabalin (200 mg) or placebo. The Neurocart was used between repeated fear‐potentiated startle assessments. Thus, the potential influence of anxiety on CNS pharmacodynamic markers could be examined. Results Compared to placebo, VAScalmness increased with alprazolam (2.0 mm) and pregabalin (2.5 mm) but not with diphenhydramine. Saccadic peak velocity (SPV) declined after alprazolam (−57 ° s–1) and pregabalin (−28 ° s–1), more than with diphenhydramine (−14 ° s–1); so did smooth pursuit. The average responses of SPV and smooth pursuit were significantly correlated with the drug‐induced increases in VAScalmness. The SPV‐relative responses of VASalertness, body‐sway and adaptive‐tracking also differed among alprazolam, pregabalin and diphenhydramine. Conclusions Compared with the antihistaminergic sedative diphenhydramine, alprazolam and pregabalin caused larger SPV reduction, which was correlated with simultaneous improvement of subjective calmness, during a study day in which anxiety was stimulated repeatedly. The different effect profiles of the three drugs are in line with their pharmacological distinctions. These findings corroborate the profiling of CNS effects to demonstrate pharmacological selectivity, and further support SPV as biomarker for anxiolysis involving GABA‐ergic neurons. The study also supports the use of prolonged mild threat to demonstrate anxiolytic effects in healthy volunteers.